Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kentucky police push for Rx-only PSE

This article was originally published in The Tan Sheet

Executive Summary

Members of the Kentucky Narcotic Officers' Association lobby for a state law to limit sales of pseudoephedrine-containing products to prescription-only to curb the growth of methamphetamine labs. In the association newsletter, President Stanley Salyards, a Louisville Metro Police sergeant, says the federal Combat Methamphtamine Act is not working, pointing to national statistics showing the number of meth labs has been on the rise since 2006. In Kentucky, the number of labs grew 55 percent in 2008 and 2009. KNOA says Oregon's 2005 decision to make PSE available prescription-only has paid off, with a "dramatic" decrease in the number of labs there. The Consumer Healthcare Products Association hopes to dissuade states from the Rx-only route by operating an electronic system for states to track sales (1"The Tan Sheet" Oct. 26, 2009)

You may also be interested in...



Industry Goes On Offensive Against Prescription Pseudoephedrine Trend

Drug firms hope to dissuade states from moving drugs that contain methamphetamine precursors to prescription status by funding electronic systems to track nonprescription sales of the products

Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles

In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.

Sobi Maintains Grip On RSV Market – For Now

Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel